Effect of Yiqi Huayu Pinggan Zishen Formula Combined with Valsartan in the Treatment of Hypertension and Its Effect on MMP-9, Ang II, and MCP-1

Author:

Yan Jing1,Li Defeng1,Liu Qin1,Xie Yuanlan1ORCID

Affiliation:

1. Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China

Abstract

Objective. To explore the effect of Yiqi Huayu Pinggan Zishen recipe combined with valsartan in the treatment of hypertension and its effect on MMP-9, Ang II, and MCP-1. Methods. About 100 patients with hypertension treated in our hospital from March 2020 to April 2021 were enrolled. All patients were arbitrarily assigned to the control group and the study group. The former group was cured with valsartan, and the latter group was cured with Yiqi Huayu Pinggan Zishen recipe combined with valsartan. The curative effect, blood pressure level, renal function index, serum matrix metalloproteinase-9 (MMP-9), monocyte chemoattractant protein-1 (MCP-1), angiotensin II (Ang II) level, traditional Chinese medicine (TCM) syndrome score, and the incidence of adverse reactions were compared. Results. First of all, we compared the curative effects; the study group exhibited remarkably effective in 44 cases and effective in 6 cases, and the effective rate was 100.00%, while in the control group, 24 cases were markedly effective, 16 cases were effective, and 5 cases were ineffective; the effective rate was 90.00%. The curative effect in the study group was higher ( P < 0.05 ). Secondly, we compared the blood pressure level. Before treatment, there was no remarkable difference ( P > 0.05 ). After treatment, the blood pressure of the two groups decreased. The systolic blood pressure and diastolic blood pressure of the study group were lower ( P < 0.05 ). In terms of renal function indexes, the levels of blood urine nitrogen (BUN), Cr, and β 2-MG in the study group were lower, while the level of eGFR in the study group was higher ( P < 0.05 ). The serum levels of MMP-9, MCP-1, and Ang II decreased. Of note, the levels of serum MMP-9, MCP-1, and Ang II in the study group were lower ( P < 0.05 ). After treatment, the TCM syndrome scores decreased, and the study group was lower ( P < 0.05 ). Finally, we compared the incidence of adverse reactions. The incidence of adverse reactions in the study group was lower ( P < 0.05 ). Conclusion. Yiqi Huayu Pinggan Zishen recipe combined with valsartan in the treatment of hypertension can remarkably reduce the clinical symptoms, enhance the renal function, strengthen the therapeutic effect, promote the ability of independent movement, and reduce the levels of serum MMP-9, MCP-1, and Ang II with high safety, which has the value of clinical application.

Publisher

Hindawi Limited

Subject

Applied Mathematics,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,Modeling and Simulation,General Medicine

Reference33 articles.

1. Clinical study of Pinggan Jiangya decoction combined with Chen Shi Baihui penetrating acupuncture in the treatment of grade 1 and 2 essential hypertension;Z. Xiaoling;Acupuncture Research,2022

2. Reticular meta analysis of clinical efficacy and safety of oral proprietary Chinese medicine combined with conventional western medicine in the treatment of hypertension;J. Zhaochen;Chinese Journal of TCM,2022

3. Traditional Chinese Medicine's liver yang ascendant hyperactivity pattern of essential hypertension and its treatment approaches: A narrative review

4. Clinical effect of Yiqi Huoxue Huayu decoction combined with routine treatment on patients with hypertensive intracerebral hemorrhage after minimally invasive operation;Q. You;Proprietary Chinese Medicine,2021

5. Effects of benazepril combined with levamlodipine besylate on vascular endothelial function and lipid peroxidation in elderly patients with hypertensive nephropathy;L. Yingli;Chinese Journal of Gerontology,2021

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3